This week on the Life Science Success podcast I am interviewed Mike Klein the CEO of Genomenon. Mike is an accomplished CEO with over 25 years of experience developing, building and growing high tech, software and IT companies. As a...
This week on the Life Science Success podcast I am interviewed Mike Klein the CEO of Genomenon. Mike is an accomplished CEO with over 25 years of experience developing, building and growing high tech, software and IT companies.
As a seasoned CEO, he draws upon a unique blend of vision, strategic thinking, communication and execution skills to help turn around and put companies on the high growth track. He has the technical and financial background to guide businesses to meet their objectives and extensive experience in raising capital, acquisitions and delivering successful investor exits.
Notes:
3:00 What does Genomenon Do?
4:00 What made Mike want to be in Life Sciences?
7:30 What are some of the lessons learned in his previous startups that he brought to Genomenon?
11:00 The importance of culture & core values
12:55 The impact Genomenon will have on the world
18:30 Advice Mike would give a new entrepreneur
20:00 Advice to someone outside of life sciences
22:50 Proudest Moment
26:32 Biggest Challenges
28:00 Three Questions
Please check out our Life Science Success Resources. You will find tools that will support growing companies and books for authors I have interviewed.
Chief Executive Officer, Genomenon
Mike is an accomplished CEO with over 25 years of experience developing, building and
growing high tech, software and IT companies.
As a seasoned CEO, he draws upon a unique blend of vision, strategic thinking, communication
and execution skills to help turn around and put companies on the high growth track. He has the
technical and financial background to guide businesses to meet their objectives and extensive
experience in raising capital, acquisitions and delivering successful investor exits.
Mike has experience as CEO of 3 different start-ups, raising over $50M in investment capital,
one acquisition, and two successful exits, including Online Tech which returned 10X to its
investors in 2012. He is now the CEO of his fourth company, Genomenon, which is an AI-driven
genomics company that organizes the world’s genomic knowledge to connect patient DNA to
scientific research in the diagnosis and development of treatments for patients with rare genetic
diseases and cancer.